
OSE Immunotherapeutics SA
PAR:OSE

OSE Immunotherapeutics SA
Pre-Tax Income
OSE Immunotherapeutics SA
Pre-Tax Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
![]() |
OSE Immunotherapeutics SA
PAR:OSE
|
Pre-Tax Income
€49.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Valneva SE
PAR:VLA
|
Pre-Tax Income
-€11.5m
|
CAGR 3-Years
45%
|
CAGR 5-Years
-68%
|
CAGR 10-Years
8%
|
|
![]() |
Nanobiotix SA
PAR:NANO
|
Pre-Tax Income
-€33.2m
|
CAGR 3-Years
9%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-15%
|
|
G
|
Genfit SA
PAR:GNFT
|
Pre-Tax Income
€22.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Inventiva SA
PAR:IVA
|
Pre-Tax Income
-€183.6m
|
CAGR 3-Years
-55%
|
CAGR 5-Years
-43%
|
CAGR 10-Years
N/A
|
|
![]() |
Eurobio Scientific SA
PAR:ALERS
|
Pre-Tax Income
€10m
|
CAGR 3-Years
-54%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
OSE Immunotherapeutics SA
Glance View
OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.

See Also
What is OSE Immunotherapeutics SA's Pre-Tax Income?
Pre-Tax Income
49.4m
EUR
Based on the financial report for Jun 30, 2024, OSE Immunotherapeutics SA's Pre-Tax Income amounts to 49.4m EUR.